NEPHROCARE HEALTH SERV L Intrinsic Value
NEPHROPLUS · Healthcare · Current price ₹619.05
Is NEPHROCARE HEALTH SERV L undervalued?
We estimate the fair value of NEPHROCARE HEALTH SERV L at ₹167 per share, against a market price of ₹765. That puts the share price about -78.2% above our estimate, at low confidence. This is our view of what the business is worth, not a target price or a forecast of where the share price will go.
How this fair value is calculated
This estimate comes from 1 method: Fair multiple (P/E) (₹167). Each is weighted by how well its inputs held up for this company. The full working, including the assumptions and what data was missing, is set out below.
The range around this estimate
Our estimate for NEPHROCARE HEALTH SERV L spans ₹150 to ₹183. That range is wide, which is the honest signal here: read the range rather than the single number. A margin of safety means buying meaningfully below the estimate: the wider the range, the more room the assumptions leave for error.
Margin of safety
Value investors look for a margin of safety: a discount to estimated value that absorbs being wrong. At ₹765 against an estimated value of ₹167, NEPHROCARE HEALTH SERV L trades at -78.2%, i.e. a premium to our estimate. How much margin to demand depends on how much you trust the inputs, which is what the confidence band below is for.
How we got this fair value
Every number below is part of the same estimate for NEPHROCARE HEALTH SERV L. Nothing here is a target price or a forecast of where the share price will go.
The inputs are thin or the models disagree sharply. This is our least reliable kind of estimate, so read the range rather than the single number.
Estimate range ₹150 – ₹183
Why this method for this business
The company is a healthcare service provider, which is asset-light and earnings-driven. A relative P/E and EV/EBITDA are appropriate for capturing its earnings power and capital structure.
The models behind the number
Each method is weighted by how well its inputs held up for this company.
required inputs missing
- dcf: Not suitable for a service provider with erratic earnings and high capital intensity
- fair multiple (P/E): Already included in relative PE model
What was missing
- Lack of forward-looking analyst estimates
- Limited historical data on earnings power
What drives it
14 inputs, grouped by how strong each claim is
- Sector-median P/E
- 34.99×
- Peers used
- 7
- EPS (TTM)
- 4.19 ₹/share
peer-median
peer-median
computed
- Term: quality
- -12.5%
- Term: growth
- +20.4%
- Term: capital_allocation
- +3.0%
- Term: financial_strength
- +3.5%
- Term: history
- +0.0%
- Term: sector_rerating
- +0.0%
- Term: rate_regime
- +1.2%
- Term: risk
- +0.0%
quality 30/100 (weak/erratic returns) → discount
durable ~28% CAGR (ROCE 8% < 12% hurdle (growth not value-accretive)) → premium
capital allocation: rising ROCE funded by strong FCF → premium
financial strength: effectively debt-free → premium
history: no reliable own-history P/E → not used
sector re-rating: no sector-norm history → not used
rates: risk-free 6.9% below ~7.1% normal → higher multiple
risk: no analyst-dispersion signal available → neutral (lowers confidence, not PE)
- Premium vs sector
- +13.6%
- Fair-multiple confidence
- 48%
- Fair P/E
- 39.75×
fundamentals + macro (not capped at own history)
data completeness + term agreement
sector median × ∏(1+term) — Dynamic Fair Multiple
Who computed this
A language model (qwen3:8b) selects the valuation method and the judgement inputs for NEPHROCARE HEALTH SERV L: which models suit the business, the moat, the growth and margin assumptions. It does not produce the number. The fair value itself is computed in Python by a deterministic engine (version 2026.08.1) from those inputs, so the same inputs always give the same result and every figure above can be traced to a source.
Estimated 14 Sept 2026. Re-run as new financials and news arrive.
How we value stocks
We estimate what a business is worth from its own economics: cash flows, returns on capital, and a multiple justified by its quality, rather than from where the share price has been. A fair value estimate is a view, not a verdict, and it is only as good as the inputs listed above.
Read the full fair-value methodologyMore on NEPHROCARE HEALTH SERV L
DocStoX estimates are computed from reported financials, for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.